We open intraday on SIGHT.PA stock at EUR 0.0839 ahead of GenSight Biologics’ scheduled earnings announcement on 20 Mar 2026. Traders are watching clinical updates and cash runway guidance. Volume today is 686,586 shares vs an average of 1,875,535. This earnings spotlight focuses on catalysts that can move the stock in the short term.
SIGHT.PA stock: earnings date and near-term catalysts
GenSight Biologics (SIGHT.PA) reports after the market on 20 Mar 2026. Investors will monitor clinical trial progress for LUMEVOQ (GS010) and any regulatory update on GS030. Management commentary on cash runway and milestones will be key. Expect headlines to drive sharp intraday moves because the company is clinical-stage and revenue is minimal.
Price action, volume and intraday context
Intraday price is EUR 0.0839, trading between a day low of EUR 0.0834 and a day high of EUR 0.0866. Today’s volume is 686,586 versus an average volume of 1,875,535, a relative volume of 0.38. The 50-day average is EUR 0.0876 and the 200-day average is EUR 0.1289, showing longer-term weakness. Short-term momentum indicators show RSI near 47.17, implying neutral bias.
Financials and valuation snapshot for SIGHT.PA stock
GenSight is loss-making with EPS -0.13 and a negative PE of -0.67. Market cap sits at EUR 16,532,528.00 and shares outstanding are 190,029,052. Key ratios: price-to-sales 17.49, book value per share -0.25, and current ratio 0.11, which signals tight liquidity. Research and development equals 10.97% of revenue, reflecting heavy clinical spend.
Meyka AI grade and model forecast for SIGHT.PA stock
Meyka AI rates SIGHT.PA with a score out of 100. Score: 72.45 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a one-year price of EUR 0.0137. Compared with the current price EUR 0.0839, that implies an ~83.65% downside. Forecasts are model-based projections and not guarantees.
Analyst signals, consensus and sector context
Third-party company rating dated 13 Mar 2026 shows a C rating with a sell recommendation on mixed valuation and balance-sheet metrics. The Healthcare sector has been weaker YTD at -6.86%, which pressures small biotechs. Risks include cash burn, trial setbacks, and low liquidity. Opportunities are strong trial readouts or licensing deals that can re-rate valuation quickly. See market comparisons on investor sites for context source.
Technical outlook and trading considerations for SIGHT.PA stock
Technical indicators show ADX 49.35, indicating a strong trend, while Bollinger Bands run 0.07–0.10 EUR, implying wide volatility. Short-term resistance sits near the 50-day average EUR 0.0876. For traders, use tight risk controls. Monitor news flow around LUMEVOQ and volume spikes. Compare peer moves via market screens to spot relative strength source.
Final Thoughts
Key takeaways for SIGHT.PA stock ahead of earnings: GenSight Biologics trades at EUR 0.0839 with low liquidity and high volatility. The company remains clinical-stage, with EPS -0.13 and pressure on the balance sheet shown by a current ratio of 0.11. Meyka AI’s model projects EUR 0.0137 for the one-year horizon, implying an ~83.65% downside versus the current price of EUR 0.0839; forecasts are model-based projections and not guarantees. Our Meyka grade, B+ (72.45) — BUY, reflects growth potential offset by execution and liquidity risks. Traders should weigh upcoming clinical updates, cash guidance, and sector weakness. For live quotes and deeper metrics, see the Meyka stock page for SIGHT.PA and combine that with official filings before trading. Meyka AI is an AI-powered market analysis platform that provides real-time signals and model outputs to inform decisions.
FAQs
When does GenSight report earnings and why does it matter for SIGHT.PA stock?
GenSight reports on 20 Mar 2026. The update matters because clinical readouts and cash guidance can cause large intraday moves in SIGHT.PA stock, given limited liquidity and the firm’s clinical-stage status.
What is Meyka AI’s forecast and how does it compare to today’s price for SIGHT.PA stock?
Meyka AI’s forecast model projects EUR 0.0137 for one year. Compared with today’s EUR 0.0839, that implies about -83.65% downside. Forecasts are model-based projections and not guarantees.
What are the main risks for investors in SIGHT.PA stock?
Primary risks include clinical trial setbacks, tight liquidity (current ratio 0.11), low average daily volume, and limited revenue. A negative trial outcome can sharply lower valuation.
Which catalysts could lift SIGHT.PA stock after the earnings release?
Positive clinical updates for LUMEVOQ or GS030, clearer cash runway, new partnerships, or pricing of a financing round could lift SIGHT.PA stock by reducing execution risk and improving liquidity.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)